Inflammation manifests itself in three main types: acute, chronic and life-threatening. It's important to understand the differences between the three, how to identify them and how to treat them.
The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...